Compounds > tak 603
Page last updated: 2024-09-04

tak 603 and Adjuvant Arthritis

tak 603 has been researched along with Adjuvant Arthritis in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baba, A; Kawamura, N; Makino, H; Ohta, Y; Sohda, T; Taketomi, S1
Baba, A; Fukuda, S; Makino, H; Nagai, H; Ohta, Y; Sohda, T; Tsukuda, R1
Makino, H; Ohta, Y; Sohda, T; Yamane, M1
Fukuda, S; Makino, H; Ohta, Y1
Baba, A; Makino, H; Ohta, Y; Sohda, T1
Baba, A; Makino, H; Mori, A; Sohda, T; Unno, S; Yasuma, T1

Other Studies

6 other study(ies) available for tak 603 and Adjuvant Arthritis

ArticleYear
Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
    Journal of medicinal chemistry, 1996, Dec-20, Volume: 39, Issue:26

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Bone Resorption; Dinoprostone; Disease Models, Animal; Female; Magnetic Resonance Spectroscopy; Male; Pregnancy; Quinazolines; Quinolines; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Structure-Activity Relationship

1996
Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603.
    Immunopharmacology, 1996, Volume: 34, Issue:1

    Topics: Adjuvants, Immunologic; Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; Cartilage; Cells, Cultured; Cytokines; Dinoprostone; Extracellular Matrix; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Quinolines; Rabbits; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Spleen; Triazoles

1996
TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis.
    Immunology, 1997, Volume: 92, Issue:1

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cell Culture Techniques; Cytokines; Dose-Response Relationship, Drug; Gene Expression; Male; Mice; Mice, Inbred A; Mice, Inbred BALB C; Ovalbumin; Quinolines; Rats; Rats, Inbred Lew; RNA, Messenger; Th1 Cells; Triazoles

1997
Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
    Immunopharmacology, 1997, Volume: 37, Issue:2-3

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; CD4-CD8 Ratio; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Lymphocyte Subsets; Male; Quinolines; Rats; Rats, Inbred Lew; Spleen; T-Lymphocytes; Triazoles

1997
Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quino line-3-carboxylate (TAK-603).
    Chemical & pharmaceutical bulletin, 1998, Volume: 46, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biotransformation; Cell Division; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Quinolines; Rats; Rats, Inbred Lew; Spleen; Triazoles

1998
Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b:5,4-c']dipyridine derivatives and their anti-inflammatory effect.
    Chemical & pharmaceutical bulletin, 1999, Volume: 47, Issue:7

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Foot; Magnetic Resonance Spectroscopy; Male; Pyridines; Quinolines; Rats; Rats, Inbred Lew; Structure-Activity Relationship; Triazoles

1999